Jim Simons’s Pasithea Therapeutics KTTA Stock Holding History

Jim Simons’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.8K	Sell	65,600 -27,799	-30%	-$19.1K	﹤0.01%	3071
2026 Q1	$69.3K	Buy	+93,399	New	+$78.1K	﹤0.01%	3074
2025 Q4	–	Sell	-30,700	Closed	-$22.5K	–	3522
2025 Q3	$22.5K	Buy	+30,700	New	+$22.4K	﹤0.01%	3416
2024 Q1	–	Sell	-1,625	Closed	-$12K	–	3907
2023 Q4	$12K	Buy	1,625 +82	+5%	+$608	﹤0.01%	3626
2023 Q3	$15K	Sell	1,543 -193	-11%	-$2.11K	﹤0.01%	3554
2023 Q2	$17K	Buy	1,736 +186	+12%	+$1.5K	﹤0.01%	3791
2023 Q1	$12K	Buy	+1,550	New	+$17.5K	﹤0.01%	3873

Other funds holding KTTA

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Jim Simons's KTTA Position: Q2 2026 in Review

Jim Simons reduced its Pasithea Therapeutics (KTTA) stake by 30% in Q2 2026, selling an estimated $19.1K and leaving 65,600 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

Jim Simons first reported a position in KTTA in Q1 2023 and has held it in 7 quarters since. The position peaked at $69.3K in Q1 2026. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

Jim Simons held 65,600 shares of Pasithea Therapeutics worth $33.8K as of Q2 2026.
Jim Simons sold 27,799 Pasithea Therapeutics shares in Q2 2026, an estimated $19.1K.
Pasithea Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #3071 holding.
Jim Simons first reported a position in Pasithea Therapeutics in Q1 2023 and has held it in 7 quarters since.
Jim Simons's Pasithea Therapeutics position peaked at $69.3K in Q1 2026.
25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.